AGECML	Advanced glycation end products–carboxymethyllysine
AMP	Antimicrobial peptide
ARDS	Acute respiratory distress syndrome
CRP	C-reactive protein
DAMP	Damage-associated molecular pattern
EIB	Exercise-induced bronchoconstriction
ELISA	Enzyme-linked immunosorbent assay
FEV1	Forced expiratory volume in one second
FVC	Forced vital capacity
HBDF2/hBD-2	Human beta-defensin 2
HCT	Hematocrit
HM	Half-marathoner(s)
HMGB1	High mobility group box 1
ICAM-1	Intercellular adhesion molecule 1
ICU	Intensive care unit
IL-1RA	Interleukin 1 receptor antagonist
IL-6	Interleukin 6
IL-33	Interleukin 33
IQR	Interquartile range
MAPK	Mitogen-activated protein kinase
MBP	Major basic protein
MEF25/50/75	Maximal expiratory flow at 25%/50%/75% of FVC
MPV	Mean platelet volume
MPO	Myeloperoxidase
MXD	Mixed cell percentage
NE	Neutrophil elastase
NF-κB	Nuclear factor kappa B
PDW	Platelet distribution width
PLT	Platelet count
RAGE	Receptor for advanced glycation end products
ROS	Reactive oxygen species
r	Correlation coefficient
SD	Standard deviation
sRAGE	Soluble receptor for advanced glycation end products
ST2	Suppression of tumorigenicity 2
Th2	T-helper cell type 2
TIFF	Tiffeneau–Pinelli index (FEV1/FVC ratio)
TLR4	Toll-like receptor 4
VEGF	Vascular endothelial growth factor
WBC	White blood cell count